<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem Med (Zagreb)</journal-id><journal-id journal-id-type="iso-abbrev">Biochem Med (Zagreb)</journal-id><journal-title-group><journal-title>Biochemia Medica</journal-title></journal-title-group><issn pub-type="ppub">1330-0962</issn><issn pub-type="epub">1846-7482</issn><publisher><publisher-name>Croatian Society of Medical Biochemistry and Laboratory Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22384527</article-id><article-id pub-id-type="pmc">4062317</article-id><article-id pub-id-type="publisher-id">biochem-med-22-1-121-14</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of the Steelex M600H coagulometer prothrombin time-international normalized ratio assay with Steelex test reagents</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Budak</surname><given-names>Yasemin U.</given-names></name><xref ref-type="aff" rid="af1-biochem-med-22-1-121-14"><sup>1</sup></xref><xref rid="c1-biochem-med-22-1-121-14" ref-type="corresp"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Huysal</surname><given-names>Ka&#x0011f;an</given-names></name><xref ref-type="aff" rid="af2-biochem-med-22-1-121-14"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Polat</surname><given-names>Murat</given-names></name><xref ref-type="aff" rid="af3-biochem-med-22-1-121-14"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tarak&#x000e7;&#x00131;</surname><given-names>G&#x000fc;lsevil</given-names></name><xref ref-type="aff" rid="af1-biochem-med-22-1-121-14"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>U&#x000e7;ar</surname><given-names>Hakan</given-names></name><xref ref-type="aff" rid="af4-biochem-med-22-1-121-14"><sup>4</sup></xref></contrib></contrib-group><aff id="af1-biochem-med-22-1-121-14"><label>1</label>Department of Clinical Laboratory, Sevket Yilmaz Education and Training Hospital, Bursa, 
<country>Turkey</country></aff><aff id="af2-biochem-med-22-1-121-14"><label>2</label>Department of Clinical Laboratory, Yuksek Ihtisas Education and Training Hospital, Bursa, 
<country>Turkey</country></aff><aff id="af3-biochem-med-22-1-121-14"><label>3</label>Department of General Surgery, Sevket Yilmaz Education and Training Hospital, Bursa, 
<country>Turkey</country></aff><aff id="af4-biochem-med-22-1-121-14"><label>4</label>Department of Cardiology, Sevket Yilmaz Education and Training Hospital, Bursa, 
<country>Turkey</country></aff><author-notes><corresp id="c1-biochem-med-22-1-121-14"><label>*</label>Corresponding author: <email>yaseminbudak2000@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>15</day><month>2</month><year>2012</year></pub-date><volume>22</volume><issue>1</issue><fpage>121</fpage><lpage>126</lpage><history><date date-type="received"><day>15</day><month>8</month><year>2011</year></date><date date-type="accepted"><day>28</day><month>12</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine.</copyright-statement><copyright-year>2012</copyright-year><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>The aim of the present study was to validate prothrombin time (PT) international normalized ratio (INR) results obtained using Steelex test reagents and a Steelex coagulometer (Steelex Scientific Instrument Company, Beijing, China), in comparison with use of a well-established standard test employing Pacific Hemostasis reagents (Fisher Diagnostics, Middletown, VA, USA) and Teco Coatron A4 coagulometer (Teco Medical Instruments GmbH, Neufahrn, Germany).</p></sec><sec sec-type="materials|methods"><title>Materials and methods:</title><p>Between- and within-day coefficients of variation (CVs) of both assays were calculated using control samples provided by the test manufacturers. Samples from 90 subjects were collected and INR values were determined in a double-blind parallel manner employing both systems.</p></sec><sec><title>Results:</title><p>The within-day coefficients of variation (CVs) in INR estimates ranged from 2.6% (INR = 1.12) to 3.1% (INR = 2.51) for the Steelex system and from 2.1% (INR = 1.09) to 1.8% (INR = 2.8) for the Pacific test; the between-day values ran from 3.4% (INR = 1.16) to 7.9% (INR = 2.64) and from 3.3% (INR = 1.1) to 2.3% (INR = 2.7), respectively. Passing-Bablok fit of the of the Steelex and Pacific methods yielded the equation: Steelex INR = 0.85 (0.79&#x02013;0.91) &#x000d7; Pacific INR + 0.12 (&#x02212;0.02&#x02013;0.21), whereas the CUSUM linearity P value was &#x0003c; 0.01. The mean bias as determined by the Bland-Altman test was &#x02212;0.156 (&#x02212;0.912&#x02013;0.600).</p></sec><sec><title>Conclusion:</title><p>The results obtained using Steelex reagents and the M600H coagulometer are not equivalent to those obtained using Pacific Hemostasis reagents and a Teco Coatron A4 coagulometer, at least in the therapeutic range.</p></sec></abstract><trans-abstract xml:lang="hr"><title>Sa&#x0017e;etak</title><sec><title>Uvod:</title><p>Cilj ovog istra&#x0017e;ivanja je validirati rezultate odre&#x00111;ivanja protrombinskog vremena (PV) me&#x00111;unarodnim normaliziranim omjerom (engl. <italic>international normalized ratio</italic>, INR) dobivene reagensima tvrtke Steelex na njihovom koagulometru (Steelex Scientific Instrument Company, Peking, Kina) u usporedbi s &#x0010d;esto primjenjivanim standardnim testom tvrtke Pacific Hemostasis (Fisher Diagnostics, Middletown, Virginia, SAD) na koagulometru proizvo&#x00111;a&#x0010d;a Teco Coatron A4 (Teco Medical Instruments GmbH, Neufahrn, Njema&#x0010d;ka).</p></sec><sec><title>Materijali i metode:</title><p>Za oba su testa izra&#x0010d;unati koeficijenti varijacije (CV) iz dana u dan i u seriji primjenjuju&#x00107;i kontrolne uzorke od proizvo&#x00111;a&#x0010d;a testa. Sakupljeni su uzorci od 90 ispitanika te su im odre&#x00111;ene INR vrijednosti dvostruko slijepim odre&#x00111;ivanjem primjenjuju&#x00107;i oba sustava.</p></sec><sec><title>Rezultati:</title><p>Koeficijenti varijacije u seriji (CV) kod odre&#x00111;ivanja INR varirali su kod Steelexovog sustava od 2,6% (INR = 1,12) do 3,1% (INR = 2,51) i kod testa tvrtke Pacific od 2,1% (INR = 1,09) do 1,8% (INR = 2,8); vrijednosti iz dana u dan su za Steelexov sustav sezale od 3,4% (INR = 1,16) to 7,9% (INR = 2,64) a za test tvrtke Pacific od 3,3% (INR = 1,1) do 2,3% (INR = 2,7). Passing Bablokovom regresijom Steelexove metode i metode proizvo&#x00111;a&#x0010d;a Pacific dobivena je jednad&#x0017e;ba: Steelex INR = 0,85 (0,79&#x02013;0,91) &#x000d7; Pacific INR + 0,12 (&#x02212;0,02&#x02013;0,21), gdje je P vrijednost CUSUM-ovog testa linearnosti bila &#x0003c; 0,01, a srednja sustavna pogrje&#x00161;ka odre&#x00111;ena Bland-Altmanovim testom iznosila je &#x02212;0,156 jedinica (&#x02212;0,912-0,600).</p></sec><sec><title>Zaklju&#x0010d;ak:</title><p>Rezultati dobiveni primjenom Steelexovih reagensa na koagulometru M600H nisu, &#x00161;to se terapeutskog raspona ti&#x0010d;e, ekvivalentni rezultatima dobivenim primjenom reagensa tvrtke Pacific Hemostasis na koagulometru Teco Coatron A4.</p></sec></trans-abstract><kwd-group><kwd>Steelex coagulometer</kwd><kwd>prothrombin time</kwd><kwd>INR</kwd><kwd>evaluation</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Prothrombin time (PT) is the most common coagulation test performed in the clinical laboratory. PT is used to detect abnormalities in the extrinsic coagulation pathway. PT measurement is critical when thrombotic patients are on oral anticoagulant therapy. However, it can be difficult to compare PT test results from different laboratories (<xref rid="b1-biochem-med-22-1-121-14" ref-type="bibr">1</xref>); standardization is essential. Thromboplastin, the principal reagent of the PT assay, is commercially available in different forms. To achieve the required standardization, all thromboplastin preparations should be calibrated using the International Sensitivity Index (ISI) and PT results should be presented in International Normalized Ratio (INR) units (<xref rid="b2-biochem-med-22-1-121-14" ref-type="bibr">2</xref>). The WHO Expert Committee on Biological Standardization has decreed that standardization requires a comparison of results yielded by the test thromboplastin with those afforded when a reference thromboplastin is employed (<xref rid="b2-biochem-med-22-1-121-14" ref-type="bibr">2</xref>,<xref rid="b3-biochem-med-22-1-121-14" ref-type="bibr">3</xref>). However, it is clear that standardization is not universally performed (<xref rid="b4-biochem-med-22-1-121-14" ref-type="bibr">4</xref>&#x02013;<xref rid="b7-biochem-med-22-1-121-14" ref-type="bibr">7</xref>).</p><p>In Turkey, public procurement law requires that the lowest bid be accepted when equipment or reagents are ordered. Thus, the choice of a coagulometer is price-dependent, even though the accuracy and reliability of INR measurement is essential. The Steelex M600H (Steelex Scientific Instrument Company, Beijing, China), approved for use in our laboratory because the device is inexpensive, is a new coagulometer that measures PT and INR.</p><p>The aim of the present study was to validate INR results obtained using the Steelex M600H coagulometer and Steelex reagents (the PT kit) by comparing such data with the results yielded by a Teco Coatron A4 coagulometer (Teco Medical Instruments GmbH, Neufahrn, Germany) employing a Pacific Hemostasis test reagent (Thromboplastin-DS, Fisher Diagnostics, VA, USA). The latter test is standard in the clinical laboratory.</p></sec><sec><title>Materials and methods:</title><p>The present study was conducted in the period from June to July 2011 in the clinical laboratory of the &#x0015e;evket Y&#x00131;lmaz Research and Education Hospital. The study was approved by our institutional Ethics Committee and all participants gave written informed consent. All procedures were in accordance with the Second Declaration of Helsinki.</p><sec sec-type="methods"><title>PT and INR determination methods</title><p>As a reference method, plasma PT was analyzed in an automated manner using a Teco Coatron A4 coagulator. The PT of citrated plasma was determined photometrically employing a high-resolution four-channel optic system (400 nm) and a suspension of rabbit brain thromboplastin (Thromboplastin-DS) prepared in calcium chloride solution. The instrument was calibrated employing calibration reference plasmas with manufacturer-assigned INR values (TECal N calibration plasma cat. no. P800-010, Teco GmbH, Germany) (<xref rid="b8-biochem-med-22-1-121-14" ref-type="bibr">8</xref>). The thromboplastin ISI value assigned by the manufacturer was 1.03. This is the method by which PT is routinely measured, in INR, in our hospital.</p></sec><sec sec-type="other"><title>Steelex M600H</title><p>PT coagulation time was measured employing a new fully automated Steelex M600H coagulometer and Steelex test reagents, and a freeze-dried extract of rabbit brain thromboplastin (product no. SS00110001; lot no. STG20101-LG4) prepared in a buffer containing calcium chloride. The ISI assigned to this preparation by the manufacturer was 1.18. In the Steelex system, light passing through a medium in which fibrinogen has been converted to fibrin is absorbed by the fibrin stands. The instrument identifies a coagulation endpoint by measuring the change in optical density at 470 nm, and this information is processed, using in-built software, to determine a clot point. The instrument was calibrated employing calibration reference plasmas with manufacturer-assigned INR values (Unicalibrator cat. no. 00675 Diagnostica Stago, Inc., France) (<xref rid="b8-biochem-med-22-1-121-14" ref-type="bibr">8</xref>). The INR is calculated and automatically displayed by the instruments from the prothrombin time using the formula (<xref rid="b3-biochem-med-22-1-121-14" ref-type="bibr">3</xref>):
<disp-formula><mml:math id="m1"><mml:mrow><mml:mtext>INR</mml:mtext><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mtext>PT</mml:mtext></mml:mrow></mml:mrow><mml:mrow><mml:mtext>sample</mml:mtext></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mtext>PT</mml:mtext></mml:mrow></mml:mrow><mml:mrow><mml:mtext>normal</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mtext>ISI</mml:mtext></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula>The coefficients of variation of the regression line slopes of calibration curves of both instruments were less than 3%, in accordance with the WHO requirements (<xref rid="b9-biochem-med-22-1-121-14" ref-type="bibr">9</xref>). All INRs were calculated using a local prothrombin time (PT); this was the mean normal prothrombin time (MNPT) obtained using 20 fresh normal samples from healthy individuals (<xref rid="b10-biochem-med-22-1-121-14" ref-type="bibr">10</xref>).</p></sec><sec sec-type="other"><title>Analytical precision of PT and INR determinations</title><p>Before specimen analysis, we performed two-level quality-control (QC) tests using materials supplied by either manufacturer (Steelex ANCP, catalog no. SS005711001 and NCP, catalog no. SS000500007; Pacific Hemostasis INR Control Plasma catalog nos. 100595 and 100596). Between-day differences in QC data were determined via analysis of duplicates on each of 20 successive days. Within-day precision was calculated by conducting 20 replicate analyses of the QC materials in a single run. Between-day precision is a measure of random analytical error (<xref rid="b11-biochem-med-22-1-121-14" ref-type="bibr">11</xref>).</p></sec><sec sec-type="other"><title>Patients and blood sampling</title><p>Venous blood samples were obtained from 90 patients for whom PT (INR) tests were scheduled as part of routine preoperative check-up (N = 14) or for monitoring of oral anticoagulant therapy (OAT) (N = 76). Patients with atrial fibrillation and/or a prosthetic heart valve, and those prescribed long-term OAT were accepted to the study. Of all patients, 35 were in their first 3 months of treatment (the dose-adjustment phase) whereas 41 were in a later treatment stage (the maintenance phase). Of all patients, the INR values of 48 were 1&#x02013;1.09 units, those of 27 2&#x02013;2.7 units, and those of 15 3&#x02013;4.9 units. Hence, all possible anticoagulation phases (pretreatment, dose-adjustment, and steady-state) were included.</p><p>Blood samples (each 1.8 mL) were collected into citrate coagulation tubes (Vacuette; Greiner Labortechnik GmbH, Krems- m&#x000fc;nster, Austria; catalog no. 454322 9NC) each containing 0.2 mL 3.2% (w/v) sodium citrate (0.109 M). Both the WHO and the NCCLS state that 3.2% (w/v) citrate is the appropriate anticoagulant level when coagulation is to be tested (<xref rid="b2-biochem-med-22-1-121-14" ref-type="bibr">2</xref>,<xref rid="b12-biochem-med-22-1-121-14" ref-type="bibr">12</xref>). Plasma was obtained via centrifugation for 15 min at 1,500 &#x000d7; g. All samples were assayed using the two systems within 1 hour of blood collection.</p></sec><sec sec-type="other"><title>Statistical analysis</title><p>Data were evaluated using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) and Analyse-It version 2.04 (Analyse-It Software, Leeds, UK). Means, standard deviations, and coefficients of variation were calculated. (<xref rid="b13-biochem-med-22-1-121-14" ref-type="bibr">13</xref>&#x02013;<xref rid="b15-biochem-med-22-1-121-14" ref-type="bibr">15</xref>).</p></sec></sec><sec><title>Results</title><p>The coefficients of variation (CVs) of within- and between-day QC data are presented in <xref rid="t1-biochem-med-22-1-121-14" ref-type="table">Table 1</xref>.</p><p>Passing and Bablok regression analysis yielded an intercept of 0.12 units (95% confidence interval (CI) = &#x02212;0.02&#x02013;0.21) and a slope of 0.85 (95% CI = 0.79&#x02013;0.91), suggesting that, a proportional difference existed between the two methods (<xref rid="f1-biochem-med-22-1-121-14" ref-type="fig">Figure 1</xref>) (<xref rid="b14-biochem-med-22-1-121-14" ref-type="bibr">14</xref>). The cumulative sum linearity test (CUSUM test) revealed significant deviation from linearity (P &#x0003c; 0.01) (<xref rid="b14-biochem-med-22-1-121-14" ref-type="bibr">14</xref>).</p><p>The Bland&#x02013;Altman difference plot showed that the mean bias was &#x02212;0.156 units and the 95% limits of agreement were &#x02212; 0.912 to 0.600 when the Steelex and Pacific test data were compared (<xref rid="f2-biochem-med-22-1-121-14" ref-type="fig">Figure 2</xref>). The bias was lower in the sub-therapeutic range (INR &#x0003c; 2.0) and higher in the therapeutic range (INR = 2.0&#x02013;4.5) (<xref rid="f1-biochem-med-22-1-121-14" ref-type="fig">Figure 1</xref>).</p></sec><sec><title>Discussion</title><p>Extensive international collaboration has allowed laboratory INR measurement to become standardized worldwide; this is an essential feature of quality control (<xref rid="b16-biochem-med-22-1-121-14" ref-type="bibr">16</xref>,<xref rid="b17-biochem-med-22-1-121-14" ref-type="bibr">17</xref>). To ensure test result accuracy, clinical laboratories are required to conduct internal quality control tests and to participate in external quality assurance (EQA) networks. Our laboratory is a member of the national external quality assessment scheme (KBUDEK, Istanbul, Turkey) that evaluates coagulation test data (PT/INR; and assays of APTT and fibrinogen). We routinely employ Pacific Hemostasis test reagents. At the time of the present study, the average values of the Standard Deviation Index (SDI; Mean minus Peer Group Mean/SD of Peer Group Mean) obtained from 134 laboratories using Pacific test reagents were 0% for an INR of 1.04 and minus 0.15% for an INR of 1.95. The SDI is a parameter for evaluating bias relative to the consensus group. It provides a good measure of accuracy because each laboratory&#x02019;s results are compared to the mean value for all laboratories, which is assumed to be the true value.</p><p>We consider that the Pacific system is a suitable standard for use in validation studies as this method yielded acceptable quality control data during our study period and employs highly sensitive human thromboplastin (ISI = 1.03), as recommended by the College of American Pathologists (<xref rid="b12-biochem-med-22-1-121-14" ref-type="bibr">12</xref>).</p><p>Within-run imprecision was satisfactory for both systems (CV &#x02264; 3.1%). The Steelex system had a higher between-run CV than did the Pacific method, explained by the fact that use of reagents of higher ISI is associated with greater interlaboratory INR CVs (<xref rid="b18-biochem-med-22-1-121-14" ref-type="bibr">18</xref>). The level of between-run imprecision using the Steelex system (Level 2; CV = 7.9%) was unacceptable; the value should be less than 5% when an INR assay is performed (<xref rid="b19-biochem-med-22-1-121-14" ref-type="bibr">19</xref>).</p><p>Monitoring of PT via calculation of INRs is important for patients on oral anticoagulation therapy; appropriate doses can thus be prescribed. Accurate INR estimation is crucial (<xref rid="b20-biochem-med-22-1-121-14" ref-type="bibr">20</xref>). Global harmonization of INR results, and agreement on the therapeutic ranges associated with varying clinical indications, is important (<xref rid="b21-biochem-med-22-1-121-14" ref-type="bibr">21</xref>). Many factors influence INR values; these include the levels of various coagulation factors present and their interaction with thromboplastin reagents differing in composition and sensitivity to the actions of such factors (<xref rid="b22-biochem-med-22-1-121-14" ref-type="bibr">22</xref>). It can be difficult to obtain accurate and precise INR measurements. Both PT and INR data should be identical regardless of the reagents, instrument, or test method used. However, agreement among results yielded by many commercial INR methods is poor. Such variations may compromise patient care (<xref rid="b1-biochem-med-22-1-121-14" ref-type="bibr">1</xref>,<xref rid="b7-biochem-med-22-1-121-14" ref-type="bibr">7</xref>).</p><p>In our present work; Passing and Bablok regression analysis yielded the appropriate y-intercept value of zero but the slope of the regression line did not approximate unity, suggesting that, in addition to the presence of a small constant bias, a proportional difference existed between the two methods (<xref rid="b14-biochem-med-22-1-121-14" ref-type="bibr">14</xref>). Our results are in agreement with previous findings of poor agreement among data obtained using different methods to calculate PT and INR (<xref rid="b7-biochem-med-22-1-121-14" ref-type="bibr">7</xref>,<xref rid="b23-biochem-med-22-1-121-14" ref-type="bibr">23</xref>). The variation noted in the present work may be attributable to differences between any or all of methodology, the coagulometers used, and thromboplastin source. Many recent reports have shown that coagulometer choice has a marked and unpredictable effect on INR value (<xref rid="b24-biochem-med-22-1-121-14" ref-type="bibr">24</xref>). The precision of PT testing tends to be greater when ISI is lower (<xref rid="b24-biochem-med-22-1-121-14" ref-type="bibr">24</xref>) but end-point reliability is also affected by reagent quality (<xref rid="b24-biochem-med-22-1-121-14" ref-type="bibr">24</xref>).</p><p>Quality control is essential; it is recommended that analytical imprecision be less than or equal to half of intra-individual biological variation (<xref rid="b25-biochem-med-22-1-121-14" ref-type="bibr">25</xref> &#x02013;<xref rid="b27-biochem-med-22-1-121-14" ref-type="bibr">27</xref>). Ricos <italic>et al</italic>. (<xref rid="b28-biochem-med-22-1-121-14" ref-type="bibr">28</xref>) found intra-individual INR variation of 4% and inter-individual variation of 6.8%. Kjeldsen (<xref rid="b29-biochem-med-22-1-121-14" ref-type="bibr">29</xref>) recorded in-treatment intra-individual INR variation of 10.1%. Via computer simulation of serial INR measurements within the generally accepted therapeutic range (INR 2.0&#x02013;3.0), the cited author concluded that analytical imprecision should be less than 5% and analytical bias less than &#x000b1; 0.2 INR units (<xref rid="b29-biochem-med-22-1-121-14" ref-type="bibr">29</xref>). In the present study, the overall analytical bias was indeed less than &#x000b1; 0.2 INR units, but, in the therapeutic range, the bias was greater than &#x000b1; 0.2 INR units, thus significantly higher than current recommendations (<xref rid="b28-biochem-med-22-1-121-14" ref-type="bibr">28</xref>,<xref rid="b29-biochem-med-22-1-121-14" ref-type="bibr">29</xref>). It is evident that ISI strongly influences INR inter-laboratory variability (<xref rid="b30-biochem-med-22-1-121-14" ref-type="bibr">30</xref>). Although the ISI assigned by the manufacturer of the Steelex M600H coagulometer was relatively low (1.18), a major limitation of our study is that local ISI calibration using WHO-certified plasma was not performed. Incorrect assignment of ISI values by manufacturers may cause among-method differences in test results.</p><p>In particular, we found that INR data obtained using either the Steelex PT or Pacific reagents were in acceptable agreement in patients with INR values close to 1, but variance within the therapeutic range (INR 2.0&#x02013;4.5) was unacceptable, with an analytical bias over 0.20 INR units (<xref rid="b19-biochem-med-22-1-121-14" ref-type="bibr">19</xref>,<xref rid="b29-biochem-med-22-1-121-14" ref-type="bibr">29</xref>) being evident in twenty eight out of 90 patients. Similarly, Horsti <italic>et al</italic>. (<xref rid="b7-biochem-med-22-1-121-14" ref-type="bibr">7</xref>) found that INR values obtained using different methods were very similar when such values were close to unity but marked variations were evident at higher INR values. This is unacceptable, because bias of this magnitude may result in prescription of incorrect amounts of anticoagulation agents (<xref rid="b9-biochem-med-22-1-121-14" ref-type="bibr">9</xref>).</p></sec><sec><title>Conclusion</title><p>In conclusion, reliable PT, INR test data are important for proper management of patients on OAT. Our results indicate that results obtained from Steelex M600H coagulometer using Steelex re-agents kit are not interchangeable with Teco Coatron A4 coagulation coagulometer using Pacific Hemostasis reagent kit, in the therapeutic range.</p></sec></body><back><ack><p>We did not receive any funding for this study.</p></ack><fn-group><fn><p><bold>Potential conflict of interest</bold></p><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-biochem-med-22-1-121-14"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>CM</given-names></name><name><surname>Esnouf</surname><given-names>MP</given-names></name></person-group><article-title>Has the time arrived to replace the quick prothrombin time test for monitoring oral anticoagulant therapy?</article-title><source>Clin Chem</source><year>2005</year><volume>51</volume><fpage>483</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15738512</pub-id></element-citation></ref><ref id="b2-biochem-med-22-1-121-14"><label>2.</label><element-citation publication-type="book"><collab>WHO Expert Committee on Biological Standardisation</collab><source>Thirty-third Report. Technical Report Series 687</source><volume>81</volume><publisher-loc>Geneva</publisher-loc><publisher-name>WHO</publisher-name><year>1983</year></element-citation></ref><ref id="b3-biochem-med-22-1-121-14"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>International Committee for Standardisation in Haematology</collab></person-group><article-title>International Committee On Thrombosis and Haemostastis. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control</article-title><source>Thromb Haemost</source><year>1985</year><volume>53</volume><fpage>155</fpage><pub-id pub-id-type="pmid">3992515</pub-id></element-citation></ref><ref id="b4-biochem-med-22-1-121-14"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>MT</given-names></name><name><surname>Johnson</surname><given-names>GF</given-names></name><name><surname>Pennell</surname><given-names>BJ</given-names></name><name><surname>Olson</surname><given-names>JD</given-names></name></person-group><article-title>The reliability of manufacturer-determined, instrument-specific international sensitivity index values for calculating the international normalized ratio</article-title><source>Am J Clin Pathol</source><year>1994</year><volume>102</volume><fpage>128</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">8037159</pub-id></element-citation></ref><ref id="b5-biochem-med-22-1-121-14"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rijn</surname><given-names>JL</given-names></name><name><surname>Schmidt</surname><given-names>NA</given-names></name><name><surname>Rutten</surname><given-names>WP</given-names></name></person-group><article-title>Correction of instrument and reagent based differences in determination of the international normalized ratio (INR) for monitoring anticoagulant therapy</article-title><source>Clin Chem</source><year>1989</year><volume>35</volume><fpage>840</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">2720982</pub-id></element-citation></ref><ref id="b6-biochem-med-22-1-121-14"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>VL</given-names></name><name><surname>Levin</surname><given-names>J</given-names></name><name><surname>Corash</surname><given-names>L</given-names></name><name><surname>Gottfried</surname><given-names>EL</given-names></name></person-group><article-title>Failure of the International Normalized Ratio to generate consistent results within a local medical community</article-title><source>Am J Clin Pathol</source><year>1993</year><volume>99</volume><fpage>689</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">8322703</pub-id></element-citation></ref><ref id="b7-biochem-med-22-1-121-14"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horsti</surname><given-names>J</given-names></name><name><surname>Uppa</surname><given-names>H</given-names></name><name><surname>Vilpo</surname><given-names>J</given-names></name></person-group><article-title>Poor agreement between different prothrombin time International Normalized Ratio (INR) methods: comparison of seven commercial reagents</article-title><source>Clin Chem</source><year>2005</year><volume>51</volume><fpage>553</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">15665046</pub-id></element-citation></ref><ref id="b8-biochem-med-22-1-121-14"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houbouyan</surname><given-names>LI</given-names></name><name><surname>Goguel</surname><given-names>AF</given-names></name></person-group><article-title>Long-term French experience in INR standardization by a procedure using plasma calibrants</article-title><source>Am J Clin Pathol</source><year>1997</year><volume>108</volume><fpage>83</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9208983</pub-id></element-citation></ref><ref id="b9-biochem-med-22-1-121-14"><label>9.</label><element-citation publication-type="book"><collab>WHO Expert Committee on Biological Standardization</collab><article-title>Annex 3: guidelines for thromboplastins and plasma used to control oral anticoagulant therapy</article-title><source>World Health Organization Technical Report Series. 48th report. No. 889</source><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>World Health Organization</publisher-name><year>1999</year><fpage>64</fpage><lpage>93</lpage></element-citation></ref><ref id="b10-biochem-med-22-1-121-14"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>RH</given-names></name><name><surname>van den Besselaar</surname><given-names>AM</given-names></name><name><surname>Olthuis</surname><given-names>FM</given-names></name></person-group><article-title>Determination of the mean normal prothrombin time for assessment of international normalized ratios. Usefulness of lyophilized plasma</article-title><source>Thromb Haemost</source><year>1991</year><volume>66</volume><fpage>442</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1796393</pub-id></element-citation></ref><ref id="b11-biochem-med-22-1-121-14"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westgard</surname><given-names>JO</given-names></name><name><surname>Carey</surname><given-names>RN</given-names></name><name><surname>Wold</surname><given-names>S</given-names></name></person-group><article-title>Criteria for judging precision and accuracy in method development and evaluation</article-title><source>Clin Chem</source><year>1974</year><volume>20</volume><fpage>825</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">4835236</pub-id></element-citation></ref><ref id="b12-biochem-med-22-1-121-14"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairweather</surname><given-names>RB</given-names></name><name><surname>Ansell</surname><given-names>J</given-names></name><name><surname>van den Besselaar</surname><given-names>AM</given-names></name><name><surname>Brandt</surname><given-names>JT</given-names></name><name><surname>Bussey</surname><given-names>HI</given-names></name><name><surname>Poller</surname><given-names>L</given-names></name><etal/></person-group><article-title>College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy</article-title><source>Arch Pathol Lab Med</source><year>1998</year><volume>122</volume><fpage>768</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">9740135</pub-id></element-citation></ref><ref id="b13-biochem-med-22-1-121-14"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bland</surname><given-names>JM</given-names></name><name><surname>Altmann</surname><given-names>DG</given-names></name></person-group><article-title>Statistical methods for assessing agreement between two methods of clinical measurement</article-title><source>Lancet</source><year>1986</year><volume>i</volume><fpage>307</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">2868172</pub-id></element-citation></ref><ref id="b14-biochem-med-22-1-121-14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilic-Zulle</surname><given-names>L</given-names></name></person-group><article-title>Comparison of methods: Passing and Bablok regression</article-title><source>Biochem Med</source><year>2011</year><volume>21</volume><fpage>49</fpage><lpage>52</lpage></element-citation></ref><ref id="b15-biochem-med-22-1-121-14"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonntag</surname><given-names>O</given-names></name></person-group><article-title>Quality in the analytical phase</article-title><source>Biochem Med</source><year>2010</year><volume>20</volume><fpage>147</fpage><lpage>53</lpage></element-citation></ref><ref id="b16-biochem-med-22-1-121-14"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Besselaar</surname><given-names>AM</given-names></name><name><surname>Barrowcliffe</surname><given-names>TW</given-names></name><name><surname>Houbouyan-R&#x000e9;veillard</surname><given-names>LL</given-names></name><name><surname>Johnston</surname><given-names>M</given-names></name><name><surname>Poller</surname><given-names>L</given-names></name><name><surname>Tripodi</surname><given-names>A</given-names></name></person-group><article-title>and On behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the ISTH. Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination</article-title><source>J Thromb Haemost</source><year>2004</year><volume>2</volume><fpage>1946</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15550026</pub-id></element-citation></ref><ref id="b17-biochem-med-22-1-121-14"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>JD</given-names></name><name><surname>Brandt</surname><given-names>JT</given-names></name><name><surname>Chandler</surname><given-names>WL</given-names></name><name><surname>Van Cott</surname><given-names>EM</given-names></name><name><surname>Cunningham</surname><given-names>MT</given-names></name><name><surname>Hayes</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Laboratory reporting of the international normalized ratio: progress and problems</article-title><source>Arch Pathol Lab Med</source><year>2007</year><volume>131</volume><fpage>1641</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17979481</pub-id></element-citation></ref><ref id="b18-biochem-med-22-1-121-14"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poller</surname><given-names>L</given-names></name><name><surname>Triplett</surname><given-names>DA</given-names></name><name><surname>Hirsh</surname><given-names>J</given-names></name><name><surname>Carroll</surname><given-names>J</given-names></name><name><surname>Clarke</surname><given-names>K</given-names></name></person-group><article-title>The value of plasma calibrants in correcting coagulometer effects on international normalized ratios&#x02014; an international multicenter study</article-title><source>Am J Clin Pathol</source><year>1995</year><volume>103</volume><fpage>358</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">7872261</pub-id></element-citation></ref><ref id="b19-biochem-med-22-1-121-14"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arkin</surname><given-names>CF</given-names></name><name><surname>Adcock</surname><given-names>DM</given-names></name><name><surname>Day</surname><given-names>HJ</given-names></name><name><surname>Carroll</surname><given-names>JJ</given-names></name><name><surname>Joist</surname><given-names>JH</given-names></name><name><surname>Lenahan</surname><given-names>JG</given-names></name><etal/></person-group><article-title>One&#x02013;stage prothrombin time (PT) Test and activated partial thromboplastin time (aPTT) test: Approved Guideline</article-title><source>NCCLS</source><year>1996</year><volume>12</volume><fpage>1</fpage><lpage>26</lpage></element-citation></ref><ref id="b20-biochem-med-22-1-121-14"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>TD</given-names></name></person-group><article-title>Self-management of oral anticoagulation therapy--methodological and clinical aspects</article-title><source>Dan Med Bull</source><year>2011</year><volume>58</volume><fpage>B4284</fpage><pub-id pub-id-type="pmid">21535992</pub-id></element-citation></ref><ref id="b21-biochem-med-22-1-121-14"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horsti</surname><given-names>J</given-names></name></person-group><article-title>Comparison of Quick and Owren prothrombin time with regard to the harmonization of the International Normalised Ratio (INR) system</article-title><source>Clin Chem Lab Med</source><year>2002</year><volume>40</volume><fpage>399</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">12059082</pub-id></element-citation></ref><ref id="b22-biochem-med-22-1-121-14"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favaloro</surname><given-names>EJ</given-names></name><name><surname>Adcock</surname><given-names>DM</given-names></name></person-group><article-title>Standardization of the INR: how good is your laboratory&#x02019;s INR and can it be improved?</article-title><source>Semin Thromb Hemost</source><year>2008</year><volume>34</volume><fpage>593</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">19085760</pub-id></element-citation></ref><ref id="b23-biochem-med-22-1-121-14"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>CM</given-names></name><name><surname>Esnouf</surname><given-names>MP</given-names></name><name><surname>Lindahl</surname><given-names>TL</given-names></name></person-group><article-title>A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy</article-title><source>Pathophysiol Haemost Thrombosis</source><year>2003</year><volume>33</volume><fpage>43</fpage><lpage>51</lpage></element-citation></ref><ref id="b24-biochem-med-22-1-121-14"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poller</surname><given-names>L</given-names></name></person-group><article-title>International Normalized Ratios (INR): the first 20 years</article-title><source>J Thromb Haemost</source><year>2004</year><volume>2</volume><fpage>849</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">15140114</pub-id></element-citation></ref><ref id="b25-biochem-med-22-1-121-14"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>JF</given-names></name><name><surname>Kjeldsen</surname><given-names>J</given-names></name><name><surname>Antonsen</surname><given-names>S</given-names></name><name><surname>Petersen</surname><given-names>PH</given-names></name><name><surname>Brandslund</surname><given-names>I</given-names></name></person-group><article-title>Interpretation of serial measurements of internalized normalized ratio for prothrombin times in monitoring oral anticoagulant therapy</article-title><source>Clin Chem</source><year>1995</year><volume>41</volume><fpage>1171</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7628093</pub-id></element-citation></ref><ref id="b26-biochem-med-22-1-121-14"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>JF</given-names></name><name><surname>Brandslund</surname><given-names>I</given-names></name><name><surname>Antonsen</surname><given-names>S</given-names></name></person-group><article-title>Determination of critical difference and probability of significant change in consecutive measurements of International Normalized Ratio (INR) from patients on oral anticoagulant therapy</article-title><source>Clin Chem</source><year>1995</year><volume>41</volume><fpage>444</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7882520</pub-id></element-citation></ref><ref id="b27-biochem-med-22-1-121-14"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricos</surname><given-names>C</given-names></name><name><surname>Perich</surname><given-names>C</given-names></name><name><surname>Minchinela</surname><given-names>J</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Biosca</surname><given-names>C</given-names></name><etal/></person-group><article-title>Application of biological variation - a review</article-title><source>Biochem Med</source><year>2009</year><volume>19</volume><fpage>250</fpage><lpage>9</lpage></element-citation></ref><ref id="b28-biochem-med-22-1-121-14"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricos</surname><given-names>C</given-names></name><name><surname>Alvarez</surname><given-names>V</given-names></name><name><surname>Cava</surname><given-names>F</given-names></name><name><surname>Garc&#x000ed;a-Lario</surname><given-names>JV</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>A</given-names></name><name><surname>Jim&#x000e9;nez</surname><given-names>CV</given-names></name><etal/></person-group><article-title>Current databases on biological variation: pros, cons and progress</article-title><source>Scand J Clin Lab Invest</source><year>1999</year><volume>66</volume><fpage>337</fpage><lpage>49</lpage></element-citation></ref><ref id="b29-biochem-med-22-1-121-14"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjeldsen</surname><given-names>J</given-names></name><name><surname>Lassen</surname><given-names>JF</given-names></name><name><surname>Petersen</surname><given-names>PH</given-names></name><name><surname>Brandslund</surname><given-names>I</given-names></name></person-group><article-title>Biological variation of International Normalised Ratio for prothrombin times, and consequences in monitoring oral anticoagulant therapy: computer simulation of serial measurements with goal-setting for analytical quality</article-title><source>Clin Chem</source><year>1997</year><volume>43</volume><fpage>2175</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">9365405</pub-id></element-citation></ref><ref id="b30-biochem-med-22-1-121-14"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabernar</surname><given-names>DA</given-names></name><name><surname>Poller</surname><given-names>L</given-names></name><name><surname>Thomson</surname><given-names>JM</given-names></name><name><surname>Darby</surname><given-names>KV</given-names></name></person-group><article-title>Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR)</article-title><source>J Clin Pathol</source><year>1989</year><volume>42</volume><fpage>92</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2921349</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-biochem-med-22-1-121-14" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Passing-Bablok regression analysis for the Steelex INR results <italic>vs</italic>. laboratory (Pacific) INR results. The solid line indicates the regression line.</p></caption><graphic xlink:href="biochem-med-22-1-121-14f1"/></fig><fig id="f2-biochem-med-22-1-121-14" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Bland-Altman plot analysis between compaired methods.</p></caption><graphic xlink:href="biochem-med-22-1-121-14f2"/></fig><table-wrap id="t1-biochem-med-22-1-121-14" orientation="portrait" position="float"><label>Table 1:</label><caption><p>Within-day imprecision data and between-day imprecision data for Steelex test reagent on Steelex M600H coagulometer and Pacific Hemostasis test reagents on Teco Coatron A4 coagulometer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="3" colspan="1"/><th align="center" valign="middle" rowspan="3" colspan="1"/><th colspan="4" align="center" valign="middle" rowspan="1"><bold>Steelex test reagents</bold></th><th colspan="4" align="center" valign="middle" rowspan="1"><bold>Pacific Hemostasis test reagents</bold></th></tr><tr><th colspan="8" align="center" valign="middle" rowspan="1">
<hr/></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1"><bold>Within-Day Mean (SD) (N = 20)</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>CV (%)</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>Between-Day Mean (SD) (N = 20)</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>CV (%)</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>Within-Day Mean (SD) (N = 20)</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>CV (%)</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>Between-Day Mean (SD) (N = 20)</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>CV (%)</bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>QC1<xref ref-type="table-fn" rid="tfn1-biochem-med-22-1-121-14">*</xref></bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>PT(sec)</bold></td><td align="center" valign="top" rowspan="1" colspan="1">13.8 (0.36)</td><td align="center" valign="top" rowspan="1" colspan="1">2.6</td><td align="center" valign="top" rowspan="1" colspan="1">14.2 (0.49)</td><td align="center" valign="top" rowspan="1" colspan="1">3.4</td><td align="center" valign="top" rowspan="1" colspan="1">15.1 (0.32)</td><td align="center" valign="top" rowspan="1" colspan="1">2.1</td><td align="center" valign="top" rowspan="1" colspan="1">15.2 (0.49)</td><td align="center" valign="top" rowspan="1" colspan="1">3.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>INR</bold></td><td align="center" valign="top" rowspan="1" colspan="1">1.12 (0.03)</td><td align="center" valign="top" rowspan="1" colspan="1">2.6</td><td align="center" valign="top" rowspan="1" colspan="1">1.16 (0.04)</td><td align="center" valign="top" rowspan="1" colspan="1">3.4</td><td align="center" valign="top" rowspan="1" colspan="1">1.09 (0.02)</td><td align="center" valign="top" rowspan="1" colspan="1">2.1</td><td align="center" valign="top" rowspan="1" colspan="1">1.1 (0.03)</td><td align="center" valign="top" rowspan="1" colspan="1">3.3</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>QC2<xref ref-type="table-fn" rid="tfn2-biochem-med-22-1-121-14">**</xref></bold></td><td align="left" valign="top" rowspan="1" colspan="1"><bold>PT(sec)</bold></td><td align="center" valign="top" rowspan="1" colspan="1">27.2 (0.71)</td><td align="center" valign="top" rowspan="1" colspan="1">2.6</td><td align="center" valign="top" rowspan="1" colspan="1">28.8 (2.19)</td><td align="center" valign="top" rowspan="1" colspan="1">7.6</td><td align="center" valign="top" rowspan="1" colspan="1">37.6 (0.68)</td><td align="center" valign="top" rowspan="1" colspan="1">1.8</td><td align="center" valign="top" rowspan="1" colspan="1">37.3 (0.86)</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>INR</bold></td><td align="center" valign="top" rowspan="1" colspan="1">2.51 (0.08)</td><td align="center" valign="top" rowspan="1" colspan="1">3.1</td><td align="center" valign="top" rowspan="1" colspan="1">2.64 (0.21)</td><td align="center" valign="top" rowspan="1" colspan="1">7.9</td><td align="center" valign="top" rowspan="1" colspan="1">2.8 (0.05)</td><td align="center" valign="top" rowspan="1" colspan="1">1.8</td><td align="center" valign="top" rowspan="1" colspan="1">2.7 (0.07)</td><td align="center" valign="top" rowspan="1" colspan="1">2.5</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-biochem-med-22-1-121-14"><label>*</label><p>QC1,</p></fn><fn id="tfn2-biochem-med-22-1-121-14"><label>*</label><p>QC2 = quality control level 1 and level 2</p></fn></table-wrap-foot></table-wrap></floats-group></article>